Joseph Berger
Neurology · Philadelphia, PANPI 1629173786
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $255,803 of the $383,616 with a category attached, or 66.7%. 26 manufacturers reported payments, led by TG Therapeutics, Inc. at 25.6% of the total. Among neurology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 396 payments — averaging $968.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- TG Therapeutics, Inc.$98K
- Gilead$50K
- Genentech, Inc.$32K
- Novartis$31K
- Sanofi$28K
- Biogen$25K
- plus $119K from 20 others
Across 44 payments — averaging $6847.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$188K
- Biogen$60K
- AstraZeneca$19K
- Gilead$13K
- Novartis$9K
- Takeda Pharmaceuticals U.S.A., Inc.$8K
- plus $5K from 1 others
What the payments were for
- Consulting fees$255,80367%
- Speaking & faculty fees$89,20723%
- Travel & lodging$24,5306%
- Food & beverage$14,0644%
- Education$130%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| TG Therapeutics, Inc. | 98 | $98,281 |
| Gilead | 20 | $49,917 |
| Genentech, Inc. | 27 | $32,326 |
| Novartis | 48 | $30,851 |
| Sanofi | 23 | $27,922 |
| Biogen | 17 | $25,056 |
| Novartis Pharma AG | 32 | $19,185 |
| Seagen Inc. | 11 | $15,100 |
| Genentech USA, Inc. | 14 | $13,077 |
| EMD Serono, Inc. | 39 | $12,819 |
| Bristol Myers Squibb | 22 | $11,402 |
| Janssen Global Services, LLC | 13 | $11,003 |
| F. Hoffmann-la Roche AG | 8 | $10,403 |
| Hoffmann-la Roche Limited | 1 | $7,200 |
| Johnson & Johnson | 1 | $4,650 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $3,265 |
| Merck Kgaa | 3 | $2,770 |
| Pfizer | 1 | $2,450 |
| Ceribell, Inc. | 1 | $1,500 |
| Cycle Pharmaceuticals Inc | 1 | $1,300 |
| Shire North American Group Inc | 2 | $1,200 |
| Hexal AG | 2 | $813 |
| Janssen Research & Development, LLC | 1 | $625 |
| E.r. Squibb & Sons, L.L.C. | 2 | $201 |
| Amgen(2 entities) | 2 | $158 |
| Abbott | 1 | $144 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BRIUMVI$88,760
- OCREVUS$43,248
- GILENYA$19,447
- KESIMPTA$14,477
- ADCETRIS$7,650
- ZEPOSIA$7,413
- DISEASE STATE$6,995
- Enspryng$5,450
- MAYZENT$3,574
- GILENYA_GILENYA_NEUROSCIENCE$3,485
- Mavenclad$2,350
- TECFIDERA$1,823
- Vumerity$1,823
- TYSABRI$1,812
- AVONEX$1,695
- PLEGRIDY$1,695
- Ceribell Rapid Response EEG$1,500
- Nityr$1,300
- Non-Covered Product$1,196
- ARZERRA$638
How this compares
$383,616 in reported general payments places this provider in the 95th percentile of 941 neurology providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 39 | $382,729 |
| AubagioTeriflunomide | 14 | $128,351 |
| Teriflunomide | 20 | $25,472 |
| Dalfampridine ErDalfampridine | 16 | $7,650 |
| Baclofen | 54 | $1,028 |
| Tolterodine Tartrate ErTolterodine Tartrate | 11 | $401 |
| Gabapentin | 15 | $207 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SanofiAubagio | $27,922 | $128,35114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 941 neurology providers in Pennsylvania.
Other neurology in Philadelphia
- Daniel KremensPhiladelphia$1.8M
- Thomas LeistPhiladelphia$1.4M
- Jill Giordano FarmerPhiladelphia$1.2M
- Stephanie Nahas-GeigerPhiladelphia$786K
- Amit Bar-OrPhiladelphia$596K
- Stephen SilbersteinPhiladelphia$428K
- Sami KhellaPhiladelphia$285K
- Clyde MarkowitzPhiladelphia$274K
- Matthew SternPhiladelphia$251K
- Michelle DoughertyPhiladelphia$236K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.